OBJECTIVE: Although prior authorization and prospective audit with feedback are both effective antimicrobial stewardship program (ASP) strategies, the relative impact of these approaches remains unclear. We compared these core ASP strategies at an academic medical center. DESIGN: Quasi-experimental study. METHODS: We compared antimicrobial use during the 24 months before and after implementation of an ASP strategy change. The ASP used prior authorization alone during the preintervention period, June 2007 through May 2009. In June 2009, many antimicrobials were unrestricted and prospective audit was implemented for cefepime, piperacillin/tazobactam, and vancomycin, marking the start of the postintervention period, July 2009 through June 2011. All adult inpatients who received more than or equal to 1 dose of an antimicrobial were included. The primary end point was antimicrobial consumption in days of therapy per 1,000 patient-days (DOT/1,000-PD). Secondary end points included length of stay (LOS). RESULTS: In total, 55,336 patients were included (29,660 preintervention and 25,676 postintervention). During the preintervention period, both total systemic antimicrobial use (-9.75 DOT/1,000-PD per month) and broad-spectrum anti-gram-negative antimicrobial use (-4.00 DOT/1,000-PD) declined. After the introduction of prospective audit with feedback, however, both total antimicrobial use (+9.65 DOT/1,000-PD per month; P < .001) and broad-spectrum anti-gram-negative antimicrobial use (+4.80 DOT/1,000-PD per month; P < .001) increased significantly. Use of cefepime and piperacillin/tazobactam both significantly increased after the intervention (P = .03). Hospital LOS and LOS after first antimicrobial dose also significantly increased after the intervention (P = .016 and .004, respectively). CONCLUSIONS: Significant increases in antimicrobial consumption and LOS were observed after the change in ASP strategy.
OBJECTIVE: Although prior authorization and prospective audit with feedback are both effective antimicrobial stewardship program (ASP) strategies, the relative impact of these approaches remains unclear. We compared these core ASP strategies at an academic medical center. DESIGN: Quasi-experimental study. METHODS: We compared antimicrobial use during the 24 months before and after implementation of an ASP strategy change. The ASP used prior authorization alone during the preintervention period, June 2007 through May 2009. In June 2009, many antimicrobials were unrestricted and prospective audit was implemented for cefepime, piperacillin/tazobactam, and vancomycin, marking the start of the postintervention period, July 2009 through June 2011. All adult inpatients who received more than or equal to 1 dose of an antimicrobial were included. The primary end point was antimicrobial consumption in days of therapy per 1,000 patient-days (DOT/1,000-PD). Secondary end points included length of stay (LOS). RESULTS: In total, 55,336 patients were included (29,660 preintervention and 25,676 postintervention). During the preintervention period, both total systemic antimicrobial use (-9.75 DOT/1,000-PD per month) and broad-spectrum anti-gram-negative antimicrobial use (-4.00 DOT/1,000-PD) declined. After the introduction of prospective audit with feedback, however, both total antimicrobial use (+9.65 DOT/1,000-PD per month; P < .001) and broad-spectrum anti-gram-negative antimicrobial use (+4.80 DOT/1,000-PD per month; P < .001) increased significantly. Use of cefepime and piperacillin/tazobactam both significantly increased after the intervention (P = .03). Hospital LOS and LOS after first antimicrobial dose also significantly increased after the intervention (P = .016 and .004, respectively). CONCLUSIONS: Significant increases in antimicrobial consumption and LOS were observed after the change in ASP strategy.
Authors: Kurt B Stevenson; Joan-Miquel Balada-Llasat; Karri Bauer; Meredith Deutscher; Debra Goff; Mark Lustberg; Preeti Pancholi; Erica Reed; David Smeenk; Jeremy Taylor; Jessica West Journal: Infect Control Hosp Epidemiol Date: 2012-04 Impact factor: 3.254
Authors: Andrew M Morris; Stacey Brener; Linda Dresser; Nick Daneman; Timothy H Dellit; Edina Avdic; Chaim M Bell Journal: Infect Control Hosp Epidemiol Date: 2012-03-20 Impact factor: 3.254
Authors: Sara E Cosgrove; Susan K Seo; Maureen K Bolon; Kent A Sepkowitz; Michael W Climo; Daniel J Diekema; Kathleen Speck; Vidhya Gunaseelan; Gary A Noskin; Loreen A Herwaldt; Edward Wong; Trish M Perl Journal: Infect Control Hosp Epidemiol Date: 2012-04 Impact factor: 3.254
Authors: Marion Elligsen; Sandra A N Walker; Ruxandra Pinto; Andrew Simor; Samira Mubareka; Anita Rachlis; Vanessa Allen; Nick Daneman Journal: Infect Control Hosp Epidemiol Date: 2012-04 Impact factor: 3.254
Authors: Pranita D Tamma; Edina Avdic; John F Keenan; Yuan Zhao; Gobind Anand; James Cooper; Rebecca Dezube; Steven Hsu; Sara E Cosgrove Journal: Clin Infect Dis Date: 2017-03-01 Impact factor: 9.079
Authors: Tamar F Barlam; Sara E Cosgrove; Lilian M Abbo; Conan MacDougall; Audrey N Schuetz; Edward J Septimus; Arjun Srinivasan; Timothy H Dellit; Yngve T Falck-Ytter; Neil O Fishman; Cindy W Hamilton; Timothy C Jenkins; Pamela A Lipsett; Preeti N Malani; Larissa S May; Gregory J Moran; Melinda M Neuhauser; Jason G Newland; Christopher A Ohl; Matthew H Samore; Susan K Seo; Kavita K Trivedi Journal: Clin Infect Dis Date: 2016-04-13 Impact factor: 9.079
Authors: Timothy C Jenkins; Bryan C Knepper; Katherine Shihadeh; Michelle K Haas; Allison L Sabel; Andrew W Steele; Michael L Wilson; Connie S Price; William J Burman; Philip S Mehler Journal: Infect Control Hosp Epidemiol Date: 2015-03-05 Impact factor: 3.254
Authors: Jennifer L Goldman; Brian R Lee; Adam L Hersh; Diana Yu; Leslie M Stach; Angela L Myers; Mary Anne Jackson; James C Day; Russell J McCulloh; Jason G Newland Journal: Infect Control Hosp Epidemiol Date: 2015-03-16 Impact factor: 3.254
Authors: Max Scheler; Thomas Lehrnbecher; Andreas H Groll; Ruth Volland; Hans-Jürgen Laws; Roland A Ammann; Philipp Agyeman; Andishe Attarbaschi; Margaux Lux; Arne Simon Journal: Infection Date: 2020-06-10 Impact factor: 3.553
Authors: Deverick J Anderson; Shera Watson; Rebekah W Moehring; Lauren Komarow; Matthew Finnemeyer; Rebekka M Arias; Jacqueline Huvane; Carol Bova Hill; Nancie Deckard; Daniel J Sexton Journal: JAMA Netw Open Date: 2019-08-02